ELI LILLY & CO (LLY)
US5324571083 - Common Stock
ELI LILLY & CO
NYSE:LLY (9/26/2023, 7:18:04 PM)
After market: 550.01 0 (0%)550.01
-2.28 (-0.41%)
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 39,000 full-time employees. The company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. The company maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
Indianapolis INDIANA 46285
P: 13172762000.0
CEO: David A. Ricks
Employees: 39000
Website: https://www.lilly.com/
LLY News
14 hours ago - ReutersUS judge overturns Eli Lilly's $176.5 million loss in Teva patent caseDrugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy. U.S. District Judge Allison Burroughs said in a post-trial ruling that the Teva patents covering the use of antibodies to inhibit headache-causing peptides were invalid. "The Court does not reach this decision nor overturn a jury verdict lightly," Burroughs said.
17 hours ago - InvestorPlaceDon’t Miss the Boom: 3 Biotech Stocks Set to Explode HigherWith their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
17 hours ago - The Motley Fool2 Magnificent Dividend Stocks to Buy Right NowThese two expensive dividend stocks are worth the price of admission.
2 days ago - The Motley Fool3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall StreetNone of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.
3 days ago - The Motley Fool3 Magnificent Growth Stocks to Buy Right NowIf you're looking for growth, these stocks could be just the ticket.
LLY Twits
Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
